$4.03
0.00%
Nasdaq, Mon, Nov 25 2024
ISIN
US37186H1005
Symbol
GTH

Genetron Holdings Ltd - ADR Stock price

$4.03
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.35 9.38% YTD
+0.34 9.08% 1Y
-27.48 87.22% 3Y
-43.98 91.61% 5Y
-43.98 91.61% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US37186H1005
Symbol
GTH
Sector

Key metrics

Market capitalization $127.29m
Enterprise Value $81.18m
EV/Sales (TTM) EV/Sales 0.96
P/S ratio (TTM) P/S ratio 1.50
Short interest 0.32%

Is Genetron Holdings Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Genetron Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Genetron Holdings Ltd - ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Genetron Holdings Ltd - ADR:

Buy
100%

Financial data from Genetron Holdings Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '22
+/-
%
97 97
17% 17%
100%
- Direct Costs 55 55
82% 82%
57%
42 42
20% 20%
43%
- Selling and Administrative Expenses 91 91
8% 8%
94%
- Research and Development Expense 43 43
9% 9%
45%
-92 -92
29% 29%
-96%
- Depreciation and Amortization 12 12
18% 18%
12%
EBIT (Operating Income) EBIT -104 -104
28% 28%
-107%
Net Profit -120 -120
56% 56%
-124%

In millions USD.

Don't miss a Thing! We will send you all news about Genetron Holdings Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Head office Cayman Islands
CEO Si Wang
Founded 2015
Website ir.genetronhealth.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today